Study approval enables Rett REVOLUTION and Pitt Hopkins clinical programs to commence patient recruitment with first dosing expected in January 2026. BOSTON--(BUSINESS WIRE)--Unravel Biosciences, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results